- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07454967
Desenvolvimento de um Sistema de IA Multimodal para Gestão de GIST
Desenvolvimento e Validação de um Modelo de Inteligência Artificial Multimodal que Integra Radiómica de TC, Patómica e Características Clínicas para o Diagnóstico, Estratificação de Risco e Previsão de Genótipo de Tumores do Estroma Gastrointestinal
Background: Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Accurate pre-operative diagnosis, risk stratification, and genotyping are critical for determining the appropriate surgical approach and targeted therapy (such as Imatinib). However, current methods often rely on invasive postoperative pathology and expensive genetic testing.
Study Objective: The purpose of this study is to develop and validate a multimodal Artificial Intelligence (AI) model that integrates clinical data, CT radiomics (imaging features), and pathomics (digital pathology features) to improve the precision of GIST management.
Study Design: This is a prospective, observational study. The researchers will recruit patients with suspected gastric submucosal tumors who are scheduled for surgery or biopsy at The Fourth Hospital of Hebei Medical University.
Core Tasks: The AI model will be trained to perform three specific tasks:
Diagnosis: Distinguish GISTs from other non-GIST mesenchymal tumors (e.g., leiomyomas, schwannomas).
Risk Assessment: Stratify GISTs into risk categories (e.g., Low vs. High risk) to predict malignant potential.
Genotyping: Predict specific gene mutations (e.g., KIT or PDGFRA mutations) to guide immunotherapy or targeted therapy.
Methodology: Patient data (CT scans, pathology slides, and clinical history) will be collected and analyzed by the AI system. The AI's predictions will be compared against the "Gold Standard" results derived from postoperative pathological examination and Next-Generation Sequencing (NGS). This study is non-interventional; the AI results will not affect the standard of care received by the patients.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Anhui
-
Fuyang, Anhui, China, 236003
- The Fifth Affiliated Hospital of Anhui Medical University
-
-
Hebei
-
Baoding, Hebei, China, 071030
- Baoding Central Hospital
-
Cangzhou, Hebei, China, 061000
- Cangzhou People's Hospital
-
Hengshui, Hebei, China, 053099
- Hengshui People's Hospital
-
Shijiazhuang, Hebei, China, 050011
- Shijiazhuang People's Hospital
-
Xingtai, Hebei, China, 054000
- The Second Affiliated Hospital of Xingtai Medical College
-
-
Hubei
-
Wuhan, Hubei, China, 430065
- Renmin Hospital of Wuhan University
-
-
Hunan
-
Hengyang, Hunan, China, 421001
- The First Affiliated Hospital of University of South China
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- Jinling Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients presenting with gastric submucosal tumors (SMTs) who are admitted to the Department of Gastrointestinal Surgery at The Fourth Hospital of Hebei Medical University for surgical or endoscopic treatment. The cohort includes patients with subsequently pathologically confirmed GISTs and other mesenchymal tumors (e.g., leiomyoma, schwannoma).
Descrição
Inclusion Criteria:
Age ≥ 18 years, gender not limited.
Clinical diagnosis of gastric submucosal tumor (SMT) or suspected gastrointestinal stromal tumor (GIST) based on gastroscopy or ultrasound.
Scheduled for surgical resection or endoscopic biopsy at the study center.
Standard preoperative contrast-enhanced CT scans are available (performed within 2 weeks prior to surgery).
Patients or their legal guardians have signed the informed consent form.
Exclusion Criteria:
Received neoadjuvant therapy (e.g., Imatinib, chemotherapy, or radiotherapy) prior to surgery/biopsy.
Poor quality of CT images (e.g., severe motion artifacts) affecting radiomics analysis.
Insufficient tissue samples for pathological diagnosis or genetic testing.
Confirmed diagnosis of other primary malignancies.
Incomplete clinical data or lost to follow-up immediately after surgery.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Diagnostic Accuracy of the AI Model for Distinguishing GIST from Non-GIST Tumors
Prazo: Up to 30 days post-surgery
|
The diagnostic accuracy is calculated as the proportion of correctly classified patients (GIST vs. Non-GIST) by the multimodal AI model, compared to the gold standard postoperative pathological diagnosis. |
Up to 30 days post-surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Concordance Rate between AI-predicted Risk Grade and Pathological Modified NIH Criteria
Prazo: Up to 30 days post-surgery
|
The proportion of patients whose risk category (Very Low/Low vs. Intermediate/High) predicted by the AI model matches the actual risk grade determined by postoperative pathology according to the modified National Institutes of Health (NIH) criteria. This will be reported as a percentage (0-100%) |
Up to 30 days post-surgery
|
|
Sensitivity and Specificity of the AI Model in Predicting KIT/PDGFRA Gene Mutations
Prazo: Up to 30 days post-surgery
|
The AI model's performance in identifying specific mutations (e.g., KIT exon 11, PDGFRA) compared to the results of Next-Generation Sequencing (NGS). Data will be reported as percentages with 95% confidence intervals. |
Up to 30 days post-surgery
|
|
Area Under the Receiver Operating Characteristic Curve (AUC) for All Tasks
Prazo: Up to 30 days post-surgery
|
The AUC values will be calculated to evaluate the overall performance of the AI model in diagnosis, risk stratification, and genotype prediction. Sensitivity and Specificity will also be reported. |
Up to 30 days post-surgery
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- GIST-DX-RISK-GEN-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .